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DORIS SCHROEDER
The highest attainable standard of health is a fundamental human right,1 which
has been part of international law since 1948.2 States and their institutions are the
primary duty bearers responsible for ensuring that human rights are respected,
protected, and fulfilled.3 However, more recently it has been argued that
pharmaceutical companies have a coresponsibility to fulfill the human right to
health.4 Most prominently, this coresponsibility has been expressed in the United
Nations (UN) Millennium Goal 8 Target 4. "In cooperation with pharmaceutical
companies, provide access to affordable essential drugs in developing coun-
tries."5
In this article, I shall examine whether this coresponsibility can be justified and,
if so, how. I start with a quick reminder of state responsibilities for the human
right to health before proceeding to assess whether pharmaceutical companies
have obligations beyond those of other corporate sectors. A simile concludes the
article.
The Human Right to Health
In December 1948, the governments of the world came together to assert that
each human being
has the right to a standard of living adequate for the health and well-
being of himself and of his family, including food, clothing, housing and
medical care and necessary social services, and the right to security in
the event of unemployment, sickness, disability, widowhood, old age or
other lack of livelihood in circumstances beyond his control.6
In 1966, this universal right to health was affirmed by linking it to national
legislation. The International Covenant on Economic, Social and Cultural Rights
commits State Parties to strive toward securing the highest attainable standard of
health for the citizens within their borders.7 However, state obligations do not
stop at the border. In Article 2, the Covenant affirms the responsibility of each
state party
to take steps, individually and through international assistance and co-
operation, especially economic and technical, to the maximum of its
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available resources, with a view to achieving progressively the full
realization of the rights recognized in the present Covenant.8
Table 1 summarizes the main legal instruments governing the right to health.
It is clear that the state bears primary responsibility for ensuring that human
rights are respected, protected, and fulfilled. However, that state institutions are
primary bearers of responsibility does not mean that other actors have no obli-
gations. The preamble to the Universal Declaration of Human Rights states that
every individual and every organ of society, keeping this Declaration
constantly in mind, shall strive by teaching and education to promote
respect for these rights and freedoms and by progressive measures,
national and international, to secure their universal and effective
recognition and observance.9
In the following, I ask whether one can reasonably assert that pharmaceutical
corporations have a coresponsibility for fulfilling the human right to health and,
if so, why.
Primary Obligations of Pharmaceutical Corporations
Pharmaceutical companies have certain obligations, two of which are primary.
The main role of a pharmaceutical company is to develop and produce in-
novative drugs and services that improve the quality of life of patients. In the
current market system, this has to be done in a profitable manner. No other
societal actor assumes this responsibility as their main task. Paul Hunt, the
former UN Special Rapporteur on the right to health formulates it thus:
A pharmaceutical company that develops a life-saving medicine has
performed a vitally important medical, public health and right-to-health
function. By saving lives, reducing suffering and improving public
health, it has not only enhanced the quality of life of individuals, but
also contributed to the prosperity of individuals, families and commu-
nities. The company, and its employees, has made a major contribution
to the realisation of the rights to life and the highest attainable standard
of health.10
Discharging this task has to be done within the legal framework. Pharmaceutical
companies must, therefore, for instance, not commit any human rights violations,
Table 1. Legal Instruments: Right to Health
Government obligations
toward their own citizens
Government obligations for
international assistance
Universal Declaration of Human Rights,
Art. 25 (1)
Declaration of Alma-Ata, Art. II
International Covenant on Economic,
Social and Cultural Rights, Art. 12
UN Committee on Economic, Social
and Cultural Rights E/C.12/2000/
4, General Comment No. 14.
Convention on the Elimination of All
Forms of Discrimination against
Women, Art. 12
Millennium Development Goals 4,
5, and 6
Convention on the Rights of the Child,
Art. 24 (1–3)
Convention on the Rights of the
Child, Art. 24 (4)
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expose employees to unhealthy and unfair working conditions, inflict damage on
the environment, or use corruption as a means to promote business or avoid
regulation.
One could term compliance with these two primary responsibilities (innova-
tion within the law) as leaving a basic ‘‘moral footprint.’’11 One could equate this
basic moral footprint with the demands of the UN Global Compact, an initiative
to encourage businesses to align their strategies with human rights law. The
Compact’s main principles are listed in Table 2
Obligations beyond the UN Global Compact?
Businesses that align their policies and conduct with the UN Global Compact are
usually commended.12 Corporations operating globally, say, a car manufacturer
or a supermarket chain, that abide conscientiously by the rules of the Compact,
would generally be regarded as fulfilling their societal and moral duties.13
However, there appears to be a difference when it comes to pharmaceutical
corporations. For the latter, there is a growing wave of demands to act beyond the
UN Global Compact and actively contribute to providing medicines for those
who cannot afford them within the market system. In the introduction, I quoted
the UN Millennium Goal 8 Target 4 ("In cooperation with pharmaceutical com-
panies, provide access to affordable essential drugs in developing countries").
Additional impetus comes from nongovernmental organizations (NGOs). For
instance, in Investing for Life: Meeting Poor People’s Needs for Access to Medicines
through Responsible Business Practices, Oxfam states:
There are major shortcomings in the pharmaceutical industry’s current
initiatives to ensure that poor people have access to medicines. . . . The
time is ripe for a bold new approach. The industry must put access to
medicines at the heart of its decision-making and practices. . . . [T]he
industry’s failure to comprehend access to medicines as a fundamental
human right enshrined in international law, and to recognise that
Table 2. UN Global Compact: The 10 Principles
Human Rights
1. Businesses should support and respect the protection of internationally proclaimed
human rights; and
2. make sure that they are not complicit in human rights abuses.
Labor Standards
3. Businesses should uphold the freedom of association and the effective recognition of the
right to collective bargaining;
4. the elimination of all forms of forced and compulsory labor;
5. the effective abolition of child labor; and
6. the elimination of discrimination in respect of employment and occupation.
Environment
7. Businesses should support a precautionary approach to environmental challenges;
8. undertake initiatives to promote greater environmental responsibility; and
9. encourage the development and diffusion of environmentally friendly technologies.
Anticorruption
10. Businesses should work against corruption in all its forms, including extortion and
bribery.
Pharmaceutical Sector and Human Right to Health
3
pharmaceutical companies have responsibilities in this context, has
prevented the adoption of appropriate strategies.14
The UN Millennium Goal 8, the Lancet editorial cited in the introduction15 and
Oxfam all assert that pharmaceutical companies have a coresponsibility to fulfill
the human right to health. I am interested here in a philosophical justification for
this assertion. Potential reasons given in the literature range from enlightened
self-interest16 to excessive profiteering,17 through ‘‘you must, if you can’’18 to
a social contract with society (i.e., patent protection in return for drugs for the
poor).19
Let us look at philanthropy motivated by enlightened self-interest first.
Although a business case can be made for such conduct, for instance to attract
better qualified staff, to satisfy ethically aware consumers or to avoid boycotts
and ‘‘shaming’’ campaigns,20 the benefit of such practices is not limited to
pharmaceutical corporations. Hence, it cannot provide justifications for special
demands on one corporate sector only. At the same time, if a clear business case
could be made for corporate human rights engagement, additional demands
would be superfluous, as businesses would engage in such behavior in an effort
to be profitable.
Likewise, excessive profits, say in the car industry, do not lead to similar
demands to provide cars to the poor. In this context, Bernard Lemoine, Director-
General of France’s National Pharmaceutical Industry, said: ‘‘I don’t see why
special effort should be demanded from the pharmaceutical industry. Nobody
asks Renault to give cars to people who haven’t got one.’’21 Of course, one can
point out that life-saving medicines provide for basic human needs; cars
normally do not. Still, if this were the only justification, car manufacturers would
have a duty to provide suitable cars where they could save lives (e.g. when given
to a midwife in rural areas of developing countries). Yet, at the same time,
exorbitant prices for basic foods, a prerequisite for human survival, do not
normally lead to requests to the food industry to provide advantageously priced
food to the poor. Instead state action is demanded, as in August 2009, when the
Indian Communist Party (CPI-M) presented demands to the government on how
to deal with high rice prices.22 It therefore does not seem to be the case that high
prices or excessive profits, however one determines these, generally lead to
demands for corporations to act beyond the UN Global Compact.
Likewise the principle of ‘‘You must, if you can’’ does not lead to general
demands on corporations to help ensure the fulfillment of human rights beyond
respecting them. If it did, food producers would have a coresponsibility to
supply sustenance to the starving. Or one might hear of demands rather than
appeals for donations to publishers or computer companies to share the
responsibility for securing the human right to education beyond their standard
business role. In fact, no target assigned to the Millennium Goals of reducing
hunger or providing universal education identifies any corporate sector re-
sponsibility.
This leaves the former UN Special Rapporteur’s justification that there is
a social contract between the pharmaceutical industry and society, a contract that
gives the privilege of patents on the one hand and demands access to drugs for
the poor on the other.23 But is this really the case? Has the pharmaceutical
industry agreed at any point to provide drugs for the poor in return for patent
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protection? If so, it is not clear how, where, or when this occurred. However,
Hunt’s justification for the special human rights obligations of the pharmaceutical
industry does refer to an important element, namely, intellectual property rights
protection.
Intellectual Property Rights and the Human Right to Health
The crux of the matter is best illustrated by comparing a company that produces
antiretroviral drugs (ARVs) with a company that produces food. In 2008, the
yearly cost of providing second-line ARVs24 to AIDS patients was US$1,105 per
patient in low income countries.25 These drugs were still under patent protection.
Hence, no cheap generic alternatives were available. To feed a child to protect
him or her from starvation or severe malnutrition costs US$630–1,260 per year,
depending on the country and the setting (and assuming the child has no
additional medical complications; personal communication, Miltos Ladikas,
figures from Action Contre La Faim (ACF), Paris on October 29, 2009). Both
the right to health and the right to food are enshrined in the same article of the
Universal Declaration of Human Rights, cited at the outset of this article.
Why then is Unilever, one of the largest multinational food producers, not
asked regularly and pressingly to contribute to achieving global food security?
What is the difference to, say, Novartis, Pfizer, or Glaxo Smith Kline’s potential to
contribute to global health? Both sectors service basic human needs, and the costs
of achieving survival are comparable.
Essentially the answer is contained in one word: patents, or, more broadly,
intellectual property right protection. Barring entry to the market for copied
products for a specified interval provides innovators with a chance to charge
monopoly prices.26 Among those who benefit from intellectual property rights
protection, the pharmaceutical industry is the only industry that trades in goods
that are required to satisfy basic human needs.27
Films, software, books, designs, circuit layouts, computer programs, new
technical inventions, and so forth, none of these satisfy basic human needs.
The only exception is the seeds industry, which does benefit from intellectual
property rights protection while providing for basic human needs. However,
considerable farmers’ rights against multinational corporations have been
established under the International Treaty on Plant Genetic Resources for Food
and Agriculture (ITPGR). This treaty exempts a number of basic food and seed
crops from patenting and makes them accessible to all member states through
a facilitated system.28 As there are no such exemptions for the pharmaceutical
industry, and countries face serious difficulties when they invoke the compulsory
licensing exemption29 of the Trade-Related Aspects of Intellectual Property
Rights Agreement (TRIPS) agreement,30 the pharmaceutical sector is unique in
benefiting from monopoly pricing powers at the same time as providing for
a basic human need. However, the situation is more complicated, and the
justification for pharmaceutical obligations is more subtle than a social contract
with patents at one end and access to drugs for the poor at the other.
It was shown in the Singer and Schroeder article in this Symposium that the
human right to life trumps any rights of inventors to have their intellectual
property protected.31 Pharmaceutical corporations cannot therefore argue that
the human right to health and the natural right to intellectual property are of
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equal value. The latter must give way to the former when they are incompatible.
However, it is one thing to build the possibility of compulsory licensing into
international law but quite another to assert a coresponsibility for securing the
human right to health. The former would be covered by the UN Global Compact,
which demands legal compliance; the latter would not.
Coresponsibility for the Human Right to Health?
To recap: I am interested in the question of why the pharmaceutical sector has
been assigned a coresponsibility to secure the human right to health. We can
disregard any arguments from benevolence or philanthropy because they would
apply to all corporate sectors. We can also ignore any arguments from unique
ability, as other companies or entities have unique abilities to contribute, for
instance, to achieving the millennium goals (e.g., food companies to eradicate
hunger [goal 1], publishers and computer firms to contribute to universal
education [goal 2]). Instead, we must keep a link between patents and basic
survival needs. A strong argument centering on harm would assert that ‘‘patents
are killing people’’32 who would live if the system were abandoned. A weaker
argument would assume that the patent system benefits many, but also directly
harms some individuals, who are owed some redress.
Although philosophers have been debating the intricacies of moral theories for
millennia, there is broad agreement that avoidable deaths constitute a harm33 and
that foreseeable harm must be avoided.34 In virtue theory ‘‘Being able to live to
the end of a human life of normal length; not dying prematurely’’35 is given
prime importance, as the first human capability that exerts a moral claim on
others.36 In utilitarian theory, it is taken for granted that ‘‘[s]uffering and death
from lack of food, shelter and medical care are bad’’ and that we must ‘‘prevent
something bad from happening.’’37 In rights-based theory it is assumed that the
"state of nature has a law . . . to govern it; . . . no one ought to harm another in his
life."38
What can one answer in response to a general attack on the patent system as
generating ‘‘profits that kill?’’39 The obvious answer is that profits for the
pharmaceutical industry are not the main justification for the patent system.
As is made clear in the preamble of the 1970’s Patent Cooperation Treaty, which
covers 142 countries,40 the reason governments support intellectual property
rights is because patents ‘‘make a contribution to the progress of science and
technology’’ and ‘‘facilitate and accelerate access by the public to the technical
information contained in documents describing new inventions.’’
Although patents are ‘‘a tortured solution to the problem of providing a public
good,’’41 no feasible alternative to a patent system seems to be on the table. This
does not mean that the system could not be improved (see Thomas Pogge and
Aidan Hollis’ epilogue to this Symposium). However, without some form of
patent system, more people could die as a result of lack of pharmaceutical
innovation.42
What can one say in response to the weaker argument that the patent system
benefits many but directly harms others to whom redress is owed? At first sight,
this does not seem to be reasonable either. Patents do not form a significant
obstacle to access to essential medicines. A study by Amir Attaran found that in
65 low- and middle-income countries, where 4 billion people live, patenting is
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rare for the 319 products on the World Health Organization’s Model List of
Essential Medicines. Only 17 essential medicines are patentable, and these are, in
practice, rarely patented, so that overall patent incidence is low (1.4%) and
concentrated in larger markets.43 Indeed, low-cost pharmaceutical interventions
that could prevent at least two thirds of today’s infant and maternal mortality are
known and available at affordable prices.44
However, as the current UN Special Rapporteur on the Right to Health, Anand
Grover, has noted,
‘[t]he inability of populations to access medicines is partly due to high
costs’;45 and that TRIPS and FTAs [Free Trade Agreements] have had an
adverse impact on prices and availability of medicines, making it
difficult for countries to comply with their obligations to respect, protect,
and fulfil the right to health.46AU1
An example, which was also included in the Schroeder and Singer piece in this
Symposium47AU2 : before 2005, Indian law only allowed patents on processes, not on
products. As a result, India had a thriving generic pharmaceuticals industry that
supplied copies of patented medicines cheaply throughout the world’s poor
regions. However, in 1994 India signed up to TRIPS and as a result, was required
to introduce patents on products by January 2005. This change to Indian patent
rules affects the world’s poor in two ways; directly by undercutting the supply of
affordable medicines and indirectly by removing the generic competition that
reduced the cost of brand-name medicines.48 These poor populations are now
worse off, and possibly dying, because of a tightening of the existing intellectual
property system. At least some of the 10 million avoidable deaths alerted to in the
editorial can therefore be attributed to current developments in the patent system.
Hence, we do have a direct, recent harm, which relates to the patent system and
which could have been avoided without the adoption of the TRIPS agreement.
The argument that intellectual property rights are a tortured solution to pro-
viding a social good, but alas necessary, does not work for those poor who may
die because of the TRIPS regime. Prior to its adoption, pharmaceutical companies
researched, developed, and produced medical interventions. It was not necessary
to adopt TRIPS to provide incentives for pharmaceutical research. But again, the
problem is more subtle than this.
High prices of drugs under patent protection are not the only problem
endangering poor people’s health. Given that the pharmaceutical industry
operates almost exclusively within the profit-making sector in line with their
primary obligation in a market system, diseases that burden the poor are often
not investigated in the first place. As noted in the introduction to this
Symposium, one can therefore speak of an accessibility problem (i.e., that existing
drugs are priced beyond the reach of the poor) and an availability problem (i.e.
that drugs are not being developed to address the needs of the poor).49 It is
assumed that stronger patent protection in countries like India, Brazil, and South
Africa will lead to the growing interest of pharmaceutical companies in so-called
neglected diseases, given that purchasing power in those countries is signifi-
cantly on the increase. Hence, although TRIPS creates direct harm for those poor
people who can no longer access cheap generic copies of patented drugs in, say,
India today, it contributes (at least potentially) to resolving the neglected diseases
issue. Going back to the pre-TRIPS regime is therefore no straightforward
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solution, morally, if one considered future benefit. At the same time, the
pharmaceutical sector benefits from a system that imposes direct harm, for
instance, on the current severely poor in India who would have had access to
generic copies of patented drugs without TRIPS.
Corporate social responsibility is usually discussed within the realm of law,
enlightened self-interest, or benevolence. Either a duty is instructed by law (e.g.,
health and safety for workers) or self-interest (e.g., continuous education of staff)
or benevolence (e.g., donations) or a mixture of the three. But for one business
sector, namely, those companies that benefit from patents on goods required to
satisfy basic needs, a fourth realm must be added, namely, a duty of redress for
harm from which one benefits.
What follows from this? The creators of the international intellectual property
rights system are policymakers, pressured by lobbyists, among them the
pharmaceutical industry.50AU3 The strongest duty to reduce any foreseeable harm
from the current patent system lies with its creators, who have to fine-tune the
system to a degree of maximum benefit and minimum harm. This work has
begun, as the article by Tikki Pang in this Symposium has shown.51 However, the
system has not only creators but also beneficiaries, most notably the pharma-
ceutical industry and those who are affluent enough to enjoy the fruits of scientific
progress. Duties of redress for harm imposed on some that achieves benefits for
others apply to both these groups. It is here that one can most reasonably apply
the ‘‘one ought, if one can’’ maxim. Pharmaceutical corporations in affluent
countries are better placed than civil society to have a fast impact on the health of
the poor. They must therefore discharge their responsibility to reduce the harm
generated by a system from which they benefit, that is, this is not a supererog-
atory act.52
We now have an answer to the question posed at the outset: does the
pharmaceutical industry have a co-responsibility for ensuring the human right
to health? Yes, it does, as it benefits from a system that foreseeably harms some of
the severely poor and therefore owes redress.53AU4 Yet, this is not a full corespon-
sibility for the human right to health per se (exempting duties for benevolence). It
is a responsibility to provide targeted redress in the one area where they benefit
from a system that creates harm; the area of access to patented medicines by
those who have now been barred as a result of the TRIPS regime.
Conclusion
Before the advent of modern medicine and drug development, one might
compare people’s lives with floating on wooden rafts on a large, unpredictable
ocean. Small cold or flu waves would throw off the weak into the ocean, and
larger pneumonia or pestilence waves would throw off even the strong. The
ocean would be teeming with small rafts, all being in the same position, fairly
defenseless against disease waves. Slowly, more reliable boats would be created,
first through traditional medicine and later by the progress of science (e.g., an
unpatented polio vaccine). Then, over a period of time, some nation states would
create huge ocean liners, almost oblivious to disease waves. Although the
creators of the ocean liners were states, certain operators would obtain rent from
all passengers, who sailed along safely with little danger of being thrown into the
ocean prematurely. Most of those drifting on small rafts were no worse off than
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before, but they would most reasonably wonder why they were left behind on
a raft. More worryingly though, the ocean liners would create an unwanted side
effect. They would create new waves that would throw some off their rafts when
they would have been able to hang on before (e.g., TRIPS and India). It is these
waves that create a duty beyond philanthropy, a duty to redress for harm done,
a limited coresponsibility for the right to access to life-saving medicines.
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